Nathan Enas

An investigational new drug treatment program for patients with gemcitabine

Anna Maria Storniolo, Nathan Enas, Cheryl A. Brown et al. · Cancer · 1999 · 261 citations

Medicine, Oncology, Pharmacotherapy +15

Phase II Study of Enzastaurin, a Protein Kinase C Beta Inhibitor, in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Michael J. Robertson, Brad S. Kahl, Julie M. Vose et al. · Journal of Clinical Oncology · 2007 · 231 citations

Medicine, Oncology, Pharmacology +15

Phase I Dose Escalation and Pharmacokinetic Study of Enzastaurin, an Oral Protein Kinase C Beta Inhibitor, in Patients With Advanced Cancer

Michael A. Carducci, Luna Musib, Merrill S. Kies et al. · Journal of Clinical Oncology · 2006 · 173 citations

Pharmacy, Oncology, Pharmacology +15

Randomization by minimization for unbalanced treatment allocation

Baoguang Han, Nathan Enas, Damian McEntegart · Statistics in Medicine · 2009 · 117 citations

Public Health, Biostatistics, Good Clinical Practice +12

Rabeprazole in Treatment of Acid Peptic Diseases (Results of Three Placebo-Controlled Dose-Response Clinical Trials in Duodenal Ulcer, Gastric Ulcer, and Gastroesophageal Reflux Disease (GERD))

M. L. Cloud, Nathan Enas, Thomas J. Humphries et al. · Digestive Diseases and Sciences · 1998 · 116 citations

Medicine, Pharmacology, Pharmacotherapy +12